ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GMAB Genmab AS

25.80
0.02 (0.08%)
After Hours
Last Updated: 16:25:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,119,737
Bid Price 25.24
Ask Price 27.37
News -
Company Name Stock Ticker Symbol Market Type
Genmab AS GMAB NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.02 0.08% 25.80 16:25:00
Open Price Low Price High Price Close Price Prev Close
26.00 25.38 26.12 25.80 25.78
Trades Volume VWAP Dollar Volume Avg Volume
9,415 2,119,737  25.54  54,128,194 -
Last Trade Time Type Quantity Stock Price Currency
16:46:31 2  26.15 USD

Genmab AS Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
15.93B 66.08M - 16.47B 4.35B 65.86 3.66
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Genmab AS

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GMAB Message Board. Create One! See More Posts on GMAB Message Board See More Message Board Posts

GMAB Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Your Recent History

Delayed Upgrade Clock